Aligos Therapeutics (ALGS) Return on Invested Capital (2021 - 2026)

Aligos Therapeutics has reported Return on Invested Capital for 6 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital rose 2.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (up 2.0% YoY), and the FY2025 full-year result was 0.0%, up 2.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.0% in Q4 2025, with the low at 0.08% in Q4 2024.
• Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.01% in 2025.
• Annual changes were most pronounced in 2024 — Return on Invested Capital retreated 7 bps — and 2025, when it increased 8 bps.
• Aligos Therapeutics' Return on Invested Capital stood at 0.01% in 2022, then slumped by 40 bps to 0.01% in 2023, then slumped by 599 bps to 0.08% in 2024, then soared by 99 bps to 0.0% in 2025, then plunged by 270 bps to 0.0% in 2026.
• The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.